Yüklüyor......
Ibrutinib in association with venetoclax for the treatment of mantle-cell lymphoma: a multicenter case series
Introduction: Mantle-cell lymphoma (MCL) with relapsed/refractory (R/R) disease after intensive chemotherapy have few effective treatment options. Ibrutinib showed a promising median progression-free survival (PFS) with manageable toxicity. The BCL2 inhibitor venetoclax showed encouraging results in...
Kaydedildi:
| Yayımlandı: | Am J Blood Res |
|---|---|
| Asıl Yazarlar: | , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
e-Century Publishing Corporation
2020
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7811909/ https://ncbi.nlm.nih.gov/pubmed/33489445 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|